[Gefitinib-induced perforating dermatosis].
Gefitinib (Iressa) is a new antineoplastic agent that acts by selectively inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). It has shown activity against several solid tumors. Because of their action mechanism, gefitinib and other tyrosine kinase inhibitors have been associated with multiple cutaneous effects, most of which are mild and well tolerated. We present a case of perforating dermatosis after treatment with gefitinib.
Fernández-Guarino
Montse
M
Servicio de Dermatología, Hospital Ramón y Cajal, Madrid, España. montsefdez@msn.com
Aldanondo
Isabel
I
González-García
Carmen
C
Garrido
Pilar
P
Marquet
Ainhoa
A
Pérez-García
Bibiana
B
Jaén
Pedro
P
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D003131:Combined Modality Therapy; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D011013:Pneumonectomy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D012883:Skin Ulcer / Q000139:chemically induced* / Q000473:pathology
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib